S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
FuelCell Is Back To Realistic Valuation
Nigeria's central bank chief arrested after being suspended by president
The single greatest medical breakthrough of all time? (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Boris Johnson's bombshell exit from Parliament leaves UK politics reeling
Can a chatbot preach a good sermon? Hundreds attend church service generated by ChatGPT to find out
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
FuelCell Is Back To Realistic Valuation
Nigeria's central bank chief arrested after being suspended by president
The single greatest medical breakthrough of all time? (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Boris Johnson's bombshell exit from Parliament leaves UK politics reeling
Can a chatbot preach a good sermon? Hundreds attend church service generated by ChatGPT to find out
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
FuelCell Is Back To Realistic Valuation
Nigeria's central bank chief arrested after being suspended by president
The single greatest medical breakthrough of all time? (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Boris Johnson's bombshell exit from Parliament leaves UK politics reeling
Can a chatbot preach a good sermon? Hundreds attend church service generated by ChatGPT to find out
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
FuelCell Is Back To Realistic Valuation
Nigeria's central bank chief arrested after being suspended by president
The single greatest medical breakthrough of all time? (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Boris Johnson's bombshell exit from Parliament leaves UK politics reeling
Can a chatbot preach a good sermon? Hundreds attend church service generated by ChatGPT to find out
NASDAQ:ARVN

Arvinas (ARVN) Stock Forecast, Price & News

$24.50
+0.25 (+1.03%)
(As of 06/9/2023 ET)
Compare
Today's Range
$23.95
$25.76
50-Day Range
$21.73
$28.54
52-Week Range
$21.21
$58.58
Volume
416,192 shs
Average Volume
364,728 shs
Market Capitalization
$1.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$67.33

Arvinas MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
174.8% Upside
$67.33 Price Target
Short Interest
Healthy
7.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Arvinas in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($6.70) to ($7.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

618th out of 987 stocks

Pharmaceutical Preparations Industry

294th out of 481 stocks


ARVN stock logo

About Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Stock News Headlines

Arvinas (NASDAQ:ARVN) Stock Price Up 4.1%
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
6 Analysts Have This to Say About Arvinas
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Arvinas (NASDAQ:ARVN) Sets New 52-Week Low at $21.86
Where Arvinas Stands With Analysts
See More Headlines

ARVN Price History

ARVN Company Calendar

Last Earnings
5/05/2023
Today
6/10/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
280
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$67.33
High Stock Price Forecast
$95.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+174.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
16 Analysts

Profitability

Net Income
$-282,500,000.00
Net Margins
-227.86%
Pretax Margin
-208.63%

Debt

Sales & Book Value

Annual Sales
$131.40 million
Book Value
$10.61 per share

Miscellaneous

Free Float
52,036,000
Market Cap
$1.31 billion
Optionable
Not Optionable
Beta
1.75

Key Executives

  • John G. HoustonJohn G. Houston
    President, Chief Executive Officer & Director
  • Lisa Sinclair
    Senior Vice President-Corporate Operations
  • Sean A. CassidySean A. Cassidy
    Chief Financial Officer
  • Ian TaylorIan Taylor
    Chief Scientific Officer
  • Ronald PeckRonald Peck
    Chief Medical Officer













ARVN Stock - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARVN shares.
View ARVN analyst ratings
or view top-rated stocks.

What is Arvinas' stock price forecast for 2023?

16 brokers have issued 12-month price targets for Arvinas' stock. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they anticipate the company's stock price to reach $67.33 in the next twelve months. This suggests a possible upside of 174.8% from the stock's current price.
View analysts price targets for ARVN
or view top-rated stocks among Wall Street analysts.

How have ARVN shares performed in 2023?

Arvinas' stock was trading at $34.21 at the beginning of 2023. Since then, ARVN stock has decreased by 28.4% and is now trading at $24.50.
View the best growth stocks for 2023 here
.

When is Arvinas' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ARVN earnings forecast
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) announced its quarterly earnings data on Friday, May, 5th. The company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by $0.05. The business earned $32.50 million during the quarter, compared to analysts' expectations of $27.74 million. Arvinas had a negative trailing twelve-month return on equity of 50.85% and a negative net margin of 227.86%. Arvinas's revenue for the quarter was up 22.6% on a year-over-year basis. During the same quarter last year, the company earned ($1.20) EPS.

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (10.71%), BlackRock Inc. (8.38%), EcoR1 Capital LLC (6.96%), Price T Rowe Associates Inc. MD (4.71%), ArrowMark Colorado Holdings LLC (2.94%) and State Street Corp (2.07%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends
.

How do I buy shares of Arvinas?

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $24.50.

How much money does Arvinas make?

Arvinas (NASDAQ:ARVN) has a market capitalization of $1.31 billion and generates $131.40 million in revenue each year. The company earns $-282,500,000.00 in net income (profit) each year or ($5.66) on an earnings per share basis.

How many employees does Arvinas have?

The company employs 280 workers across the globe.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.

This page (NASDAQ:ARVN) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -